Hepatic Complications in obesity (NAFLD)

Previous activities

The aim of the present team, composed of clinicians and research scientists, is to better understand the hepatic complications associated with obesity (Non Alcoholic Fatty Liver Disease: NAFLD) and/or chronic alcohol consumption (Alcoholic Liver Disease, ALD). These chronic liver diseases range from steatosis to steatohepatitis (Non Alcoholic or Alcoholic Steatohepatitis, NASH and ASH respectively), fibrosis, cirrhosis and finally hepatocellular carcinoma. NAFLD and ALD are the main causes of cirrhosis and increase the risk of liver-related death and hepatocellular carcinoma. NASH and ALD are also the most common indications for liver transplantation.

Research Projects

Our translational research mainly focuses on:

1) The identification of new markers/actors in the progression of NAFLD and ALD in humans by taking advantage of our cohorts of obese (n=1006) and alcoholic patients (n=173) and through « omics » approaches;

2) The study of potential cellular and molecular players regulating inflammation, cell death and/or metabolism responsible for NAFLD progression. More specifically, our studies focus on osteopontin/CD44, endoplasmic reticulum stress and sirtuin-6 signaling pathways and are investigated by cellular and mouse models;

3) The study of the interaction between alcohol and obesity in the severity of fatty liver disease in mice and humans.

The results of the present project should bring new insights to the overall understanding of hepatic complications induced by obesity and chronic alcohol consumption in order to propose better diagnostic and new therapeutic approaches.

Scheme Team 8 23 11 2016

Team Publications